ENSG00000062822 |
|
colon adenocarcinoma |
missense_variant |
4.695% (60/1278) |
9 entries |
ENSG00000062822 |
|
colon adenocarcinoma |
sequence_alteration |
4.695% (60/1278) |
1 entry |
ENSG00000062822 |
|
colorectal adenocarcinoma |
stop_gained |
5.243% (69/1316) |
1 entry |
ENSG00000062822 |
|
colorectal adenocarcinoma |
missense_variant |
5.243% (69/1316) |
9 entries |
ENSG00000062822 |
|
colon adenocarcinoma |
stop_gained |
4.695% (60/1278) |
2 entries |
ENSG00000062822 |
|
colon adenocarcinoma |
frameshift_variant |
4.695% (60/1278) |
6 entries |
ENSG00000062822 |
|
colorectal adenocarcinoma |
frameshift_variant |
5.243% (69/1316) |
2 entries |
ENSG00000062822 |
|
colorectal adenocarcinoma |
sequence_alteration |
5.243% (69/1316) |
2 entries |
ENSG00000062822 |
|
anaplastic oligodendroglioma |
missense_variant |
2.326% (2/86) |
1 entry |
ENSG00000062822 |
|
melanoma |
missense_variant |
2.759% (4/145) |
2 entries |
ENSG00000062822 |
|
B-cell acute lymphoblastic leukemia |
missense_variant |
3.704% (2/54) |
1 entry |
ENSG00000062822 |
|
Endometrial Endometrioid Adenocarcinoma |
stop_gained |
2.381% (20/840) |
2 entries |
ENSG00000062822 |
|
lung adenocarcinoma |
sequence_alteration |
1.063% (29/2727) |
1 entry |
ENSG00000062822 |
|
esophageal adenocarcinoma |
missense_variant |
2.742% (15/547) |
2 entries |
ENSG00000062822 |
|
Endometrial Endometrioid Adenocarcinoma |
missense_variant |
2.381% (20/840) |
2 entries |
ENSG00000062822 |
|
ovarian serous adenocarcinoma |
missense_variant |
0.2401% (2/833) |
2 entries |
ENSG00000062822 |
|
breast carcinoma |
missense_variant |
0.7968% (12/1506) |
2 entries |
ENSG00000062822 |
|
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma |
missense_variant |
0.7576% (2/264) |
1 entry |
ENSG00000062822 |
|
lobular breast carcinoma |
missense_variant |
1.21% (3/248) |
2 entries |
ENSG00000062822 |
|
cecum adenocarcinoma |
missense_variant |
4.528% (12/265) |
2 entries |
ENSG00000062822 |
|
Merkel cell skin cancer |
missense_variant |
2.151% (2/93) |
2 entries |
ENSG00000062822 |
|
female breast carcinoma |
missense_variant |
1.124% (3/267) |
1 entry |
ENSG00000062822 |
|
clear cell renal carcinoma |
missense_variant |
0.534% (8/1498) |
3 entries |
ENSG00000062822 |
|
bladder transitional cell carcinoma |
missense_variant |
2.418% (11/455) |
2 entries |
ENSG00000062822 |
|
pancreatic ductal adenocarcinoma |
missense_variant |
1.367% (23/1683) |
2 entries |
ENSG00000062822 |
|
Cervical Small Cell Carcinoma |
missense_variant |
25.0% (2/8) |
1 entry |
ENSG00000062822 |
|
head and neck squamous cell carcinoma |
missense_variant |
0.9539% (6/629) |
1 entry |
ENSG00000062822 |
|
bladder carcinoma |
missense_variant |
1.068% (6/562) |
1 entry |
ENSG00000062822 |
|
hepatocellular carcinoma |
missense_variant |
1.117% (11/985) |
1 entry |
ENSG00000062822 |
|
skin melanoma |
missense_variant |
1.897% (22/1160) |
5 entries |
ENSG00000062822 |
|
non-small cell lung carcinoma |
missense_variant |
2.083% (2/96) |
2 entries |
ENSG00000062822 |
|
brain glioblastoma |
missense_variant |
0.5477% (7/1278) |
2 entries |
ENSG00000062822 |
|
acute myeloid leukemia |
missense_variant |
0.5929% (6/1012) |
1 entry |
ENSG00000062822 |
|
prostate adenocarcinoma |
sequence_alteration |
0.8376% (18/2149) |
1 entry |
ENSG00000062822 |
|
gastric intestinal type adenocarcinoma |
missense_variant |
2.353% (2/85) |
1 entry |
ENSG00000062822 |
|
basal cell carcinoma |
missense_variant |
4.412% (3/68) |
1 entry |
ENSG00000062822 |
|
breast carcinoma |
frameshift_variant |
0.7968% (12/1506) |
1 entry |
ENSG00000062822 |
|
prostate carcinoma |
sequence_alteration |
1.174% (5/426) |
1 entry |
ENSG00000062822 |
|
lung adenocarcinoma |
missense_variant |
1.063% (29/2727) |
5 entries |
ENSG00000062822 |
|
head and neck squamous cell carcinoma |
sequence_alteration |
0.9539% (6/629) |
1 entry |
ENSG00000062822 |
|
cecum adenocarcinoma |
sequence_alteration |
4.528% (12/265) |
2 entries |
ENSG00000062822 |
|
diffuse large B-cell lymphoma |
missense_variant |
0.5391% (2/371) |
2 entries |
ENSG00000062822 |
|
small cell lung carcinoma |
missense_variant |
1.357% (6/442) |
3 entries |
ENSG00000062822 |
|
prostate adenocarcinoma |
missense_variant |
0.8376% (18/2149) |
2 entries |
ENSG00000062822 |
|
oral squamous cell carcinoma |
missense_variant |
1.908% (5/262) |
4 entries |
ENSG00000062822 |
|
urothelial carcinoma |
missense_variant |
4.651% (4/86) |
1 entry |
ENSG00000062822 |
|
gastric adenocarcinoma |
missense_variant |
2.222% (16/720) |
1 entry |
ENSG00000062822 |
|
squamous cell lung carcinoma |
missense_variant |
0.6438% (6/932) |
1 entry |
ENSG00000062822 |
|
endometrial carcinoma |
missense_variant |
1.471% (1/68) |
1 entry |
ENSG00000062822 |
|
chronic myelomonocytic leukemia |
missense_variant |
3.704% (1/27) |
1 entry |
ENSG00000062822 |
|
prostate carcinoma |
frameshift_variant |
1.174% (5/426) |
1 entry |
ENSG00000062822 |
|
skin melanoma |
sequence_alteration |
1.897% (22/1160) |
1 entry |
ENSG00000062822 |
|
bladder transitional cell carcinoma |
stop_gained |
2.418% (11/455) |
1 entry |
ENSG00000062822 |
|
Sinonasal Undifferentiated Carcinoma |
missense_variant |
8.333% (1/12) |
1 entry |
ENSG00000062822 |
|
chronic lymphocytic leukemia |
sequence_alteration |
0.2245% (2/891) |
1 entry |
ENSG00000062822 |
|
Anal Squamous Cell Carcinoma |
missense_variant |
1.22% (1/82) |
1 entry |
ENSG00000062822 |
|
bile duct adenocarcinoma |
missense_variant |
0.1603% (1/624) |
1 entry |
ENSG00000062822 |
|
papillary thyroid carcinoma |
missense_variant |
0.2045% (1/489) |
1 entry |
ENSG00000062822 |
|
anaplastic astrocytoma |
sequence_alteration |
1.449% (2/138) |
1 entry |
ENSG00000062822 |
|
Gallbladder Adenocarcinoma |
sequence_alteration |
0.5917% (1/169) |
1 entry |
ENSG00000062822 |
|
brain glioblastoma |
sequence_alteration |
0.5477% (7/1278) |
1 entry |
ENSG00000062822 |
|
small cell lung carcinoma |
frameshift_variant |
1.357% (6/442) |
1 entry |
ENSG00000062822 |
|
Invasive Breast Carcinoma |
missense_variant |
2.222% (1/45) |
1 entry |
ENSG00000062822 |
|
basal cell carcinoma |
sequence_alteration |
4.412% (3/68) |
1 entry |
ENSG00000062822 |
|
glioma |
sequence_alteration |
0.3257% (2/614) |
1 entry |
ENSG00000062822 |
|
Mixed Lobular and Ductal Breast Carcinoma |
missense_variant |
1.408% (1/71) |
1 entry |
ENSG00000062822 |
|
breast ductal adenocarcinoma |
stop_gained |
1.319% (22/1668) |
1 entry |
ENSG00000062822 |
|
colon carcinoma |
missense_variant |
12.5% (1/8) |
1 entry |
ENSG00000062822 |
|
breast ductal adenocarcinoma |
frameshift_variant |
1.319% (22/1668) |
1 entry |
ENSG00000062822 |
|
mucosal melanoma |
missense_variant |
1.429% (1/70) |
1 entry |
ENSG00000062822 |
|
clear cell renal carcinoma |
sequence_alteration |
0.534% (8/1498) |
1 entry |
ENSG00000062822 |
|
undifferentiated pleomorphic sarcoma |
missense_variant |
1.613% (1/62) |
1 entry |
ENSG00000062822 |
|
Tracheal Squamous Cell Carcinoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000062822 |
|
lung adenocarcinoma |
frameshift_variant |
1.063% (29/2727) |
1 entry |
ENSG00000062822 |
|
esophageal adenocarcinoma |
frameshift_variant |
2.742% (15/547) |
1 entry |
ENSG00000062822 |
|
skin melanoma |
frameshift_variant |
1.897% (22/1160) |
1 entry |
ENSG00000062822 |
|
Duodenal Adenocarcinoma |
frameshift_variant |
5.882% (1/17) |
1 entry |
ENSG00000062822 |
|
cecum adenocarcinoma |
conservative_inframe_deletion |
4.528% (12/265) |
1 entry |
ENSG00000062822 |
|
small intestinal adenocarcinoma |
missense_variant |
4.762% (1/21) |
1 entry |
ENSG00000062822 |
|
Gastric Diffuse Large B-Cell Lymphoma |
missense_variant |
50.0% (1/2) |
1 entry |
ENSG00000062822 |
|
small cell lung carcinoma |
sequence_alteration |
1.357% (6/442) |
1 entry |
ENSG00000062822 |
|
endometrium adenocarcinoma |
missense_variant |
3.571% (1/28) |
1 entry |
ENSG00000062822 |
|
breast ductal adenocarcinoma |
missense_variant |
1.319% (22/1668) |
1 entry |
ENSG00000062822 |
|
anaplastic astrocytoma |
missense_variant |
1.449% (2/138) |
1 entry |
ENSG00000062822 |
|
nasopharyngeal squamous cell carcinoma |
missense_variant |
0.5556% (1/180) |
1 entry |
ENSG00000062822 |
|
colorectal adenoma |
missense_variant |
7.692% (1/13) |
1 entry |
ENSG00000062822 |
|
Duodenal Adenocarcinoma |
missense_variant |
5.882% (1/17) |
1 entry |
ENSG00000062822 |
|
cecum adenocarcinoma |
frameshift_variant |
4.528% (12/265) |
1 entry |